ArticleInflammatory bowel diseases2023

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.

Yoram Bouhnik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.